Related Experiment Video
Updated: Jun 9, 2026
Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm
Published on: December 22, 2016
Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms
Philip A Beer1, Christina A Ortmann, Frank Stegelmann
1Cambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Hills Road, Cambridge, UK.
Abstract:
Somatic activating mutations in MPL, the thrombopoietin receptor, occur in the myeloproliferative neoplasms, although virtually nothing is known about their role in evolution to acute myeloid leukemia. In this study, the MPL T487A mutation, identified in de novo acute myeloid leukemia, was not detected in 172 patients with a myeloproliferative neoplasm. In patients with a prior MPL W515L-mutant myeloproliferative neoplasm, leukemic transformation was accompanied by MPL-mutant leukemic blasts, was seen in the absence of prior cytoreductive therapy and often involved loss of wild-type MPL by mitotic recombination. Moreover, clonal analysis of progenitor colonies at the time of leukemic transformation revealed the presence of multiple genetically distinct but phylogenetically-related clones bearing different TP53 mutations, implying a mutator-phenotype and indicating that leukemic transformation may be preceded by the parallel expansion of diverse hematopoietic clones.
Insights
Somatic mutations in MPL (thrombopoietin receptor) are key in myeloproliferative neoplasms. Leukemic transformation involves MPL mutations and loss of wild-type MPL, alongside diverse TP53-mutant clones.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Somatic activating mutations in MPL, the thrombopoietin receptor, are implicated in myeloproliferative neoplasms (MPNs).
- The precise role of MPL mutations in the evolution of MPNs to acute myeloid leukemia (AML) remains largely unknown.
- MPL mutations, such as W515L, are established drivers in certain MPNs.
Purpose of the Study:
- To investigate the role of MPL mutations in the leukemic transformation of MPNs.
- To characterize the genetic landscape of acute myeloid leukemia (AML) arising from MPNs.
- To explore the mechanisms underlying the evolution from MPN to AML.
Main Methods:
- Analysis of MPL mutations in de novo AML and MPN patient cohorts.
- Genomic analysis of leukemic transformation in patients with prior MPL W515L-mutant MPNs.
- Clonal analysis of progenitor colonies using TP53 mutation profiling.
Main Results:
- The MPL T487A mutation was identified in de novo AML but not in MPN patients.
- Leukemic transformation in MPL W515L-mutant MPNs was associated with MPL-mutant leukemic blasts and loss of wild-type MPL via mitotic recombination.
- Clonal analysis revealed multiple distinct, phylogenetically related clones with different TP53 mutations during leukemic transformation, suggesting a mutator phenotype.
Conclusions:
- MPL mutations play a role in the leukemic transformation of MPNs, often involving loss of the wild-type allele.
- TP53 mutations and a mutator phenotype may precede or accompany leukemic transformation.
- The parallel expansion of diverse hematopoietic clones contributes to the evolution of MPN to AML.
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
02:23Abnormal Proliferation
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...